Gregory J Privitera

Jan 24, 2024 | clinicalleader.com | Gregory J Privitera |Stuart Redding |Kerry Leyden

YPrime unveils a transformative brand focused on ‘Solving for Certainty’ in clinical trials. Experience the reimagined brand and explore the solutions that transform clinical research at www.yprime.com. The 3 Big Downsides To DCTsExamine three overlapping categories of concern when it comes to decentralized clinical trials: consent and selection, user experience, and comfort and privacy.

Jan 8, 2024 | clinicalleader.com | Gregory J Privitera

By James Gillespie, Ph.D., and Gregory Privitera, Ph.D. Decentralized clinical trials (DCTs) are increasingly used by sponsors and CROs, with the COVID-19 pandemic having rapidly accelerated that trend. In fact, hybrid or fully virtual modalities are now becoming the norm rather than a crisis-driven exception. DCTs offer several potential benefits. However, the industry should be thoughtful as it embraces decentralization.